Navigation Links
CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology
Date:5/26/2009

VIENNA, Va. May 26 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM) announced today that it is developing an immune-based treatment for the "swine flu and related H1N1" flu viruses, utilizing its proprietary L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) vaccine technology. The Company plans to utilize the expertise and knowledge it has gained from developing protective and therapeutic vaccines utilizing L.E.A.P.S. to develop a therapeutic treatment based upon the technology for people infected with the swine and H1N1 flu viruses. CEL-SCI has already commenced pre-clinical testing.

Previously, CEL-SCI announced that its CEL-1000 peptide, which is derived from the L.E.A.P.S. technology, showed adjuvant activity when used with a peptide based malaria vaccine and a DNA based malaria vaccine in animal challenge studies as part of a Cooperative Research arrangement with the Naval Medical Research Center, Silver Spring, MD. In both cases, the addition of CEL-1000 to the vaccines resulted in significant increases in the protection of the animals. In addition, several different L.E.A.P.S. conjugates induced protection and/or improvement in diseases as diverse as rheumatoid arthritis, malaria, TB and herpes simplex viruses. This shows that the L.E.A.P.S. technology can be successfully applied to many different diseases and these results further suggest that L.E.A.P.S. has the potential to be used either alone as a therapy or as an adjuvant to vaccines under development for the treatment of H1N1 related flu viruses. Adjuvants are designed to improve the effectiveness of vaccines.

"We believe that our L.E.A.P.S. technology platform offers strong potential to address the current swine and H1N1 flu viruses," said Dr. Daniel Zimmerman of CEL-SCI, the inventor of the technology. "With the swine flu currently cr
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
2. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
3. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
4. CEL-SCI Corporation Announces 2008 Financial Results
5. CEL-SCI Corporation Releases Letter to Shareholders
6. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
7. CEL-SCI Takes Delivery of New Manufacturing Facility
8. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
9. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
10. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
11. CEL-SCI to Present at the Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015 Bionomics Limited (ASX:BNO, ADR:BMICY) ... trial of BNC105 in patients with metastatic renal cancer ... Orlando, Florida . The data will be presented ... of Hope Comprehensive Cancer Center in California ... The new data identifies Ferritin and IL-8 as two ...
(Date:2/27/2015)... FamilyFarms Group is pleased to announce ... Line Farms, received the 2015 Tomorrow’s Top Producer Horizon ... age of 35, who has demonstrated excellence in the ... win the Tomorrow's Top Producer Horizon Award. Every year ... Producer Award and learning from their experiences. It is ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Steep Hill, ... the US and internationally, intends to open a full ... Albuquerque, New Mexico , bringing advanced scientific tools ... cannabis. Steep Hill is currently the only ... to conduct potency and contaminant testing in order to ...
(Date:2/26/2015)... 26, 2015 S&P Capital IQ (MHFI) announced ... coverage on MabVax Therapeutics Holdings Inc . ... stage biotechnology company focused on the development of vaccine ... the treatment of cancer. MabVax has discovered a pipeline ... immune responses generated by patients who have been immunized ...
Breaking Biology Technology:New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5
... Dedicating this year,s,Venture Forum to the life sciences industry, ... in developing and producing the 2008,Life Sciences Venture Forum, ... early-stage life sciences companies from the U.S. and,around the ... place on,May 30, 2008, at the Santa Clara Convention ...
... Neurosciences,Inc. (OTC Bulletin Board: ILNS), announced today that ... the grant requirements to obtain a,European patent relating ... by the Company for the treatment of Alzheimer,s,disease. ... several weeks. Other,patents related to the ANTISENILIN(R) antibodies ...
... 10 /PRNewswire-FirstCall/ - Oncothyreon Inc.,(Nasdaq: ONTY ) ... PX-478, pharmacodynamic studies of PX-12 and preclinical studies ... of the American Association,for Cancer Research (AACR) in ... currently conducting a Phase 1 clinical trial of ...
Cached Biology Technology:Larta Institute Partners With Burrill & Company to Present the 14th Annual Life Sciences Venture Forum 2Larta Institute Partners With Burrill & Company to Present the 14th Annual Life Sciences Venture Forum 3Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease 2Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease 3Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease 4Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting 2Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting 3
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... Calif. , Jan. 27, 2015 /PRNewswire/ ... provider of globally deployed, innovative test solutions ... announced the delivery of its TS-323 ... Space Systems Company (LMSSC). GENASYS is a ... demands of mission-critical applications that require performance ...
(Date:2/5/2015)... VIEW, Calif. , Feb. 3, 2015 /PRNewswire/ ... printer technology, demand from industries such as consumer ... global market for surface mount technology (SMT) screen ... equipment to automatic control will push the adoption ... dispensers will remain steady as glue dispensers are ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3
... step in the ongoing battle against secondhand tobacco smoke. They ... immediately detect the presence of secondhand smoke and even third-hand ... about the size of a matchbox car, the device uses ... A sensor chip then records the data on an SD ...
... University] A key advance, newly reported by chemists ... cheaper and more sustainable way to make acrylate, an ... fabrics to diapers. Chemical companies churn out billions ... propylene, a compound derived from crude oil. "What we,re ...
... after the FDA approved Kalydeco (Vx-770), the first drug of ... University of Missouri researchers believe they have found exactly how ... the future. Described in the current issue of the ... have redefined a key regulatory process in the defective protein ...
Cached Biology News:Scientists create new tools for battling secondhand smoke 2Scientists create new tools for battling secondhand smoke 3Breakthrough could lead to cheaper, more sustainable chemical production 2Discovery could increase efficacy of promising cystic fibrosis drug 2Discovery could increase efficacy of promising cystic fibrosis drug 3Discovery could increase efficacy of promising cystic fibrosis drug 4
Metamine is an autonomous data mining tool that extends the capabilities of conventional research teams. It is a proactive agent that searches for significant results buried within the GeNet data rep...
... Oxidative stress is the condition in which ... oxidant stimuli and the various antioxidants. Oxidative ... the pathogenesis of several diseases, including artherosclerosis, ... body possesses several antioxidant systems that are ...
... PolarScreen Progesterone Receptor (PR) Competitor Assay ... screening novel progesterone receptor binding compounds ... assay utilizes a fusion of glutathione ... of human progesterone receptor [PR-LBD(GST)] and ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential CV/Renal liabilities of compounds....
Biology Products: